Michelle Glaser
About Michelle Glaser
Michelle Glaser is a Territory Business Manager at Alkermes in Las Vegas, Nevada, with extensive experience in neuroscience and antipsychotic sales.
Current Role at Alkermes
Michelle Glaser is the Territory Business Manager at Alkermes in Las Vegas, Nevada. In this role, she promotes injectable antipsychotic Aristada for treating schizophrenia and has launched Lybalvi, a new antipsychotic medication. She currently ranks #32 out of 316 nationally, demonstrating her proficiency in sales and product promotion.
Past Experience in Neurology Sales
Before her current role, Michelle Glaser worked at Allergan Botox Neurology as an Executive Neuroscience Sales Specialist from 2012 to 2015. During her tenure in Bergen County, New Jersey, she focused on product training and marketing related to neuroscientific products, gaining significant experience in this specialized field.
Previous Positions at Alkermes and Smith & Nephew
Michelle Glaser held positions as a Territory Business Manager at Alkermes in the Greater New York City Area and Brooklyn, New York from 2015 to 2021. Before that, she was a Territory Account Manager at Smith & Nephew from 2011 to 2012, where she managed client relationships and product sales in the New York City Metropolitan Area.
Educational Background
Michelle Glaser holds a Bachelor of Business Administration (B.B.A.) from the University of California, Irvine. She also studied for a Master of Business Administration (MBA) at the University of Phoenix. Her educational background in business administration has equipped her with essential skills for her extensive career in sales and territory management.
Sales Skills and Achievements
Michelle Glaser has a proven track record of exceeding sales goals and achieving revenue growth for over 15 years. She is skilled in delivering education and training at various medical facilities including hospital operating rooms, mental health treatment centers, and VA hospitals. She has earned yearly sales awards, top national rankings, and year-over-year revenue growth in neuroscience, antipsychotics, and rare disease specialties.